Stockscreener 앱 받기
0.3787
8.77%
-0.0364
Vaxart Inc 주식(VXRT)의 최신 뉴스
Vaxart Resumes COVID-19 Vaccine Trial After Government Lift - TipRanks
Vaxart (VXRT) Advances Vaccine Efforts Amid Market Challenges | VXRT Stock News - GuruFocus
Vaxart seeks stockholder approval for reverse split - Investing.com
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress - The Manila Times
Vaxart CEO Letter: Government Lifts Trial Hold, Norovirus Study Fully Enrolled, Cash Extended to 2026 - Stock Titan
Vaxart to Host First Quarter 2025 Business Update and Financial - GuruFocus
Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13 - GlobeNewswire
Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13 | VXRT Stock News - GuruFocus
Vaxart, Inc. to Host Conference Call for Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Vaxart Sets Q1 2025 Earnings Call Date: How to Join the May 13 Investor Update - Stock Titan
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate - GlobeNewswire
Vaxart to Present at the Citizens Life Sciences Conference - GlobeNewswire
Exclusive: Vaxart Leadership Takes Stage at Citizens Life Sciences ConferenceKey Updates Expected - Stock Titan
Vaxart (VXRT) Completes Enrollment for Phase 1 Norovirus Vaccine Trial | VXRT Stock News - GuruFocus
Vaxart Completes Enrollment In Phase 1 Trial For Its Norovirus Oral Pill Vaccine Candidate - marketscreener.com
Vaxart completes enrollment for oral norovirus vaccine trial By Investing.com - Investing.com India
Vaxart completes enrollment for oral norovirus vaccine trial - Investing.com
Vaxart's Novel Oral Norovirus Vaccine Hits Major Milestone: Phase 1 Trial Fully Enrolled, Data Coming Mid-2025 - Stock Titan
Vaxart resumes BARDA-funded trial activities By Investing.com - Investing.com Canada
Vaxart says it can resume next-gen Covid work, will screen participants for oral vaccine trial - Endpoints News
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Federal government lifts hold on Peninsula biotech company's vaccine trial - The Business Journals
Vaxart resumes BARDA-funded trial activities - Investing.com
Vaccine biotechs say they’ve been told to stop next-gen Covid work under a Biden-era project - Endpoints News
Biota Pharmaceuticals to Present at Stifel 2015 Healthcare Conference - marketscreener.com
Vaxart to Present at World Vaccine Congress Washington 2025 on April 23 - GlobeNewswire
Vaxartto Present at World Vaccine Congress Washington 2025 on April 23 - The Manila Times
Revolutionary Oral Tablet Vaccines: Vaxart Reveals Latest Breakthrough Data at Major Congress - Stock Titan
Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com
Proprietary - Vaxart Inc.
VXRT stock touches 52-week low at $0.31 amid market challenges - Investing.com Australia
VXRT stock touches 52-week low at $0.31 amid market challenges By Investing.com - Investing.com South Africa
RFK Jr. pauses $240 million contract for new ‘oral COVID vaccine’ - Todayville
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vaxart reports inducement grants under Nasdaq listing rule - TipRanks
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges - Investing.com
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges By Investing.com - Investing.com South Africa
Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vaxart's Major Talent Investment: 659,500 Share Awards and Key Executive Hire Signals Growth - Stock Titan
B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating - MarketScreener
Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript - Insider Monkey
Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Oral - Vaxart Inc.
Sudden Trump administration order prompts Bay Area company to lay off staff - SFGATE
Bay Area biotech company lays off staff over sudden Trump admin order - SFGATE
5.24%
자본화:
|
볼륨(24시간):